PKDL is a dermal form of leishmaniasis caused by protozoal parasite Leishmania donovani, spread through the bite of infected female Phlebotomine sand flies. It is characterized by macular, papular, or nodular lesions or a mixture of these. There are very limited drugs available for the treatment of PKDL.The present treatment guideline includes miltefosine in the dose of 2.5mg/kg/day or 100mg/day for 12 weeks. However, this drug is associated with gastrointestinal side effects and contraindicated in pregnant and nourishing women due to its teratogenic effect.  Recently a study by Ramesh et. al reported that the efficacy of miltefosine is decreasing substantially in the treatment of PKDL with a cure rate of 85%.  The other alternative treatment is with amphotericin B in the dose of 1mg/kg in 5% dextrose IV, alternate days for 15 injections in 3 to 4 courses at fifteen days intervals .This treatment regimen is very lengthy, requires prolonged hospitalization and has severe side effects including nephrotoxicity and hypokalemia. Liposomal formulation of amphotericin B has a longer half life, less toxic and recommended by WHO for elimination of VL from the Indian subcontinent. Liposomal amphotericin B at 2.5mg/kg for 20 days was tried in Sudanese PKDL.Cure rate was 83% and no adverse events were reported, Similarly a study was done in Bangladesh  with Ambisome by MSF(unpublished). Despite  high endemicity of the disease in India no study was done on PKDL with Ambisome. Therefore, we aimed to assess the efficacy and safety of Liposomal Amphotericin B in the treatment of PKDL in Bihar and compare it with the standard treatment of PKDL with Miltefosine 2.5 mg/kg body weight or 100 mg/day for 12 weeks. This study can proved to be one of the benchmark for establishing an effective, safe and shorter duration treatment for PKDL in the Indian subcontinent, which in turn will be of great help for the kalaazar elimination program.